Pharmacologic inhibition of platelet function: Correlation between in vitro tests of platelet function and clinical outcomes

American Journal of Cardiovascular Drugs

Volumn 8, Issue 5, 2008, Pages 283-295

  Ashley, Kellan E ^a   Lincoff, A Michael ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Abciximab, therapeutic use; Aspirin, therapeutic use; Cardiovascular disorders, treatment; Clopidogrel, therapeutic use; Eptifibatide, therapeutic use; Platelet ADP receptor antagonists, therapeutic use; Platelet aggregation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN; WARFARIN;

AGGREGOMETRY; ATHEROSCLEROSIS; BLEEDING TIME; BLOOD CLOT LYSIS; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DEVICE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; FLOW CYTOMETRY; HUMAN; LABORATORY TEST; LOADING DRUG DOSE; MEASUREMENT; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK REDUCTION; STANDARD; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TURBIDIMETRY;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TREATMENT OUTCOME;

EID: 53149099720     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808050-00001     Document Type: Review

References (119)

1. Ruggeri ZM. Platelets in atherothrombosis. Nature Med 2002 Nov; 8 (11): 1227-34
2. Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967 Sep 2; 2 (7514): 495-7
3. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975 Aug; 72 (8): 3073-6
4. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991 Sep 3; 68 (7): 11B-5B
5. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975 Aug; 72 (8): 2994-8
6. Lewis Jr HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983 Aug 18; 309 (7): 396-403
7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspiring, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988 Aug 13; 2 (8607): 349-60
8. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989 Jul 20; 321 (3): 129-35
9. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk: the Medical Research Council's General Practice Research Framework. Lancet 1998 Jan 24; 351 (9098): 233-41
10. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755-62
11. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991 Jul 24-31; 266 (4): 521-7
12. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005 Mar 31; 352 (13): 1293-304
13. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994 Jan 8; 308 (6921): 81-106
14. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan 12; 324 (7329): 71-86
15. Aspirin in coronary heart disease: the Coronary Drug Project Research Group. J Chronic Dis 1976 Oct; 29 (10): 625-42
16. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1974 Mar 9; 1 (5905): 436-40
17. Persantine and aspirin in coronary heart disease: the Persantine-Aspirin Reinfarction Study Research Group. Circulation 1980 Sep; 62 (3): 449-61
18. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet 1979 Dec 22-9; 2 (8156-8157): 1313-5
19. Breddin K, Loew D, Lechner K, on behalf of the German-Austrian Study Group, et al. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation 1980 Dec; 62 (6 Pt 2): V63-72
20. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994 Jan 15; 308 (6922): 159-68
21. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988 Jun 30; 318 (26): 1714-9
22. Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990 Feb 15; 65 (7): 422-6
23. Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery: a placebo-controlled, randomized study. Circulation 1991 May; 83 (5): 1526-33
24. Goldman S, Copeland J, Moritz T, et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 1988 Jun; 77 (6): 1324-32
25. Stein PD, Dalen JE, Goldman S, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 1998 Nov; 114 (5 Suppl.): 658S-65S
26. International Stroke Trial Collaborative Group, et al. The International Stroke Trial (IST): a randomised trial of aspirin subcutaneous heparin both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997 May 31; 349 (9065): 1569-81
27. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke: CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997 Jun 7; 349 (9066): 1641-9
28. Bousser MG, Eschwege E, Haguenau M, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983 Jan-Feb; 14 (1): 5-14
29. Swedish Aspirin Low-Dose Trial (SALT) of 75mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events: the SALT Collaborative Group. Lancet 1991 Nov 30; 338 (8779): 1345-9
30. Tijssen JG. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. Neurology 1998 Sep; 51 (3 Suppl. 3): S15-6
31. Mills DC, Puri R, Hu CJ, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992 Apr; 12 (4): 430-6
32. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998 Sep 1; 129 (5): 394-405
33. Berger PB. Aspirin, ticlopidine and clopidogrel in and out of the catheterization laboratory. J Invasive Cardiol 1999 Jun; 11 Suppl. A: 20A-9A
34. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989 Jun 3; 1 (8649): 1215-20
35. Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989 Aug 24; 321 (8): 501-7
36. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990 May; 227 (5): 301-8
37. Arcan JC, Blanchard J, Boissel JP, et al. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988 Sep; 39 (9): 802-11
38. Blanchard J, Carreras LO, Kindermans M. Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev Fr Hematol 1994; 35 (6): 523-8
39. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990 Jul; 82 (1): 17-26
40. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation 1998 Nov 17; 98 (20): 2126-32
41. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996 Apr 25; 334 (17): 1084-9
42. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998 Dec 3; 339 (23): 1665-71
43. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation 1998 Oct 20; 98 (16): 1597-603
44. Schomig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997 Jan; 29 (1): 28-34
45. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE): CAPRIE Steering Committee. Lancet 1996 Nov 16; 348 (9038): 1329-39
46. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999 May 11; 99 (18): 2364-6
47. Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999 Dec; 34 (7): 1891-4
48. Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000 Feb 15; 101 (6): 590-3
49. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001 Jul 31; 104 (5): 539-43
50. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 Aug 16; 345 (7): 494-502
51. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001 Aug 18; 358 (9281): 527-33
52. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA Nov 20; 288 (19): 2411-20
53. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005 Mar 24; 352 (12): 1179-89
54. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005 Sep 14; 294 (10): 1224-32
55. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 Apr 20; 354 (16): 1706-17
56. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998 Dec 22-29; 98 (25): 2829-35
57. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty: the EPIC Investigation. N Engl J Med 1994 Apr 7; 330 (14): 956-61
58. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: the EPILOG Investigators. N Engl J Med 1997 Jun 12; 336 (24): 1689-96
59. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty: randomized efficacy study of tirofiban for outcomes and restenosis. Circulation 1997 Sep 2; 96 (5): 1445-53
60. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998 Jul 11; 352 (9122): 87-92
61. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999 May 27; 340 (21): 1623-9
62. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, et al. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter trial. Circulation 1996 Nov 1; 94 (9): 2083-9
63. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998 May 21; 338 (21): 1498-505
64. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998 May 21; 338 (21): 1488-97
65. Michelson AD, Frelinger 3rd AL, Furman MI. Current options in platelet function testing. Am J Cardiol 2006 Nov 20; 98 (10A): 4N-10N
66. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004 Nov 9; 110 (19): e489-93
67. Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001 May 29; 103 (21): 2572-8
68. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004 Mar 17; 43 (6): 1122-6
69. Harrison P, Segal H, Blasbery K, et al. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005 May; 36 (5): 1001-5
70. Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004 Jan; 35 (1): 175-8
71. Hezard N, Metz D, Nazeyrollas P, et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thrombosis Haemostasis 2000 Apr; 83 (4): 540-4
72. Madan M, Berkowitz SD, Christie DJ, et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001 Feb; 141 (2): 226-33
73. Madan M, Berkowitz SD, Christie DJ, et al. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 2002 Jul; 144 (1): 151-8
74. Hayward CP, Harrison P, Cattaneo M, et al. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006 Feb; 4 (2): 312-9
75. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007 Nov 6; 50 (19): 1822-34
76. Quick AJ. Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci 1966 Sep; 252 (3): 265-9
77. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995 Mar; 11 (3): 221-7
78. Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J 1998; 32 (4): 233-7
79. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function: implications for clinical trials and therapy. Arch Pathol Lab Med 1994 Aug; 118 (8): 801-4
80. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients: evidence of nonresponders in a subpopulation of treated patients. Thrombosis Res 1991 Sep 15; 63 (6): 587-93
81. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thrombosis Haemostasis 1997 Sep; 78 (3): 1003-7
82. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003 Aug; 1 (8): 1710-3
83. McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002 Nov; 88 (5): 711-5
84. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001 Aug 1; 88 (3): 230-5
85. Cotter G, Shemesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004 Feb; 147 (2): 293-300
86. Becker RC, Burns M, Gore JM, et al. Early and pre-discharge aspirin administration among patients with acute myocardial infarction: current clinical practice and trends in the United States. J Thromb Thrombolysis 2000 Apr; 9 (3): 207-15
87. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation 1994 Oct; 90 (4): 2103-14
88. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med 1996 Feb 1; 124 (3): 292-8
89. Califf RM, DeLong ER, Ostbye T, et al. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol 2002 Mar 15; 89 (6): 653-61
90. Zimmermann N, Kienzle P, Weber AA, et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001 May; 121 (5): 982-4
91. Christiaens L, Macchi L, Herpin D, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thrombosis Res 2002 Nov 1; 108 (2-3): 115-9
92. Muller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003 May; 89 (5): 783-7
93. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003 Jun 17; 107 (23): 2908-13
94. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006 Jan 3; 47 (1): 27-33
95. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005 Jan 18; 45 (2): 246-51
96. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004 Jan 20; 109 (2): 166-71
97. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004 Apr; 16 (4): 169-74
98. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001 Jul; 86 (1): 222-32
99. Labarthe B, Theroux P, Angioi M, et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005 Aug 16; 46 (4): 638-45
100. Yee DL, Sun CW, Bergeron AL, et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005 Oct 15; 106 (8): 2723-9
101. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder: a pilot-study including 180 post-stroke patients. Thromb Res 1993 Sep 1; 71 (5): 397-403
102. Andersen K, Hurlen M, Arnesen H, et al. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002 Oct 1; 108 (1): 37-42
103. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002 Sep 26; 347 (13): 969-74
104. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 Apr 9; 105 (14): 1650-5
105. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003 Mar 19; 41 (6): 961-5
106. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007 Jul; 120 (7): 631-5
107. Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003 May; 59 (1): 21-5
108. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004 Jun 29; 109 (25): 3171-5
109. Bonello L, Paganelli F, Arpin-Bornet M, et al. VASP phosphorylation analysis prior to percutaneous coronary intervention for exclusion of post-procedural major adverse cardiovascular events. J Thromb Haemost 2007 Aug; 5 (8): 1630-6
110. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342 (3): 145-53
111. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998 Feb; 31 (2): 241-51
112. Steinhubl SR, Kottke-Marchant K, Moliterno DJ, et al. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 1999 Nov 9; 100 (19): 1977-82
113. Sirotkina OV, Khaspekova SG, Zabotina AM, et al. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists. Platelets 2007 Nov; 18 (7): 506-14
114. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006 Oct; 152 (4): 627-35
115. Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000 Apr; 129 (7): 1439-46
116. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007 Jan; 153 (1): 66 e9-16
117. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006 May; 27 (10): 1166-73
118. Serebruany VL, Midei MG, Meilman H, et al. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006 Jun; 82 (968): 404-10
119. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 Nov 15; 357 (20): 2001-15